These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25858582)

  • 1. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
    Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
    Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
    [No Abstract]   [Full Text] [Related]  

  • 2. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decitabine studies in chronic and acute myelogenous leukemia.
    Kantarjian HM; O'Brien SM; Estey E; Giralt S; Beran M; Rios MB; Keating M; de Vos D; Talpaz M
    Leukemia; 1997 Mar; 11 Suppl 1():S35-6. PubMed ID: 9130691
    [No Abstract]   [Full Text] [Related]  

  • 4. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
    Fenaux P; Mufti GJ; Hellström-Lindberg E; Santini V; Gattermann N; Germing U; Sanz G; List AF; Gore S; Seymour JF; Dombret H; Backstrom J; Zimmerman L; McKenzie D; Beach CL; Silverman LR
    J Clin Oncol; 2010 Feb; 28(4):562-9. PubMed ID: 20026804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
    Bohl SR; Dolnik A; Jensen T; Lang KM; Hackanson B; Gaidzik VI; Paschka P; Knudsen S; Döhner K; Döhner H; Claus R; Lübbert M; Bullinger L
    Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278722
    [No Abstract]   [Full Text] [Related]  

  • 7. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
    Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
    Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence for a role of decitabine in the treatment of myeloid sarcoma.
    Gornicec M; Wölfler A; Stanzel S; Sill H; Zebisch A
    Ann Hematol; 2017 Mar; 96(3):505-506. PubMed ID: 27817041
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine. Acute myeloid leukaemia: no progress.
    Prescrire Int; 2014 Apr; 23(148):92-4. PubMed ID: 24860891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
    Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
    Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
    Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
    Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
    Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract]   [Full Text] [Related]  

  • 16. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
    Schwartsmann G; Fernandes MS; Schaan MD; Moschen M; Gerhardt LM; Di Leone L; Loitzembauer B; Kalakun L
    Leukemia; 1997 Mar; 11 Suppl 1():S28-31. PubMed ID: 9130689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
    Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.
    Ramos F; Thépot S; Pleyer L; Maurillo L; Itzykson R; Bargay J; Stauder R; Venditti A; Seegers V; Martínez-Robles V; Burgstaller S; Récher C; Debén G; Gaidano G; Gardin C; Musto P; Greil R; Sánchez-Guijo F; Fenaux P;
    Leuk Res; 2015 Mar; 39(3):296-306. PubMed ID: 25601157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.